167 related articles for article (PubMed ID: 27351223)
1. Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.
Sui H; Shi C; Yan Z; Wu M
Oncotarget; 2016 Jul; 7(29):45995-46001. PubMed ID: 27351223
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of cathepsin L sensitizes ovarian cancer cells to chemotherapy.
Zhang H; Zhang L; Wei L; Gao X; Tang LI; Gong W; Min NA; Zhang LI; Yuan Y
Oncol Lett; 2016 Jun; 11(6):4235-4239. PubMed ID: 27313771
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
Cui F; Wang W; Wu D; He X; Wu J; Wang M
Clin Transl Oncol; 2016 Jul; 18(7):722-7. PubMed ID: 26474873
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.
Han ML; Zhao YF; Tan CH; Xiong YJ; Wang WJ; Wu F; Fei Y; Wang L; Liang ZQ
Acta Pharmacol Sin; 2016 Dec; 37(12):1606-1622. PubMed ID: 27840408
[TBL] [Abstract][Full Text] [Related]
6. A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.
Zhao YF; Han ML; Xiong YJ; Wang L; Fei Y; Shen X; Zhu Y; Liang ZQ
Acta Pharmacol Sin; 2018 Jun; 39(6):1034-1047. PubMed ID: 29219949
[TBL] [Abstract][Full Text] [Related]
7. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between cathepsin L and invasion and metastasis of ovarian carcinoma cells].
Wang SM; Li L; Zhang W; Li DR; Tang BJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):598-602. PubMed ID: 21029616
[TBL] [Abstract][Full Text] [Related]
9. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
10. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin L-mediated resistance of paclitaxel and cisplatin is mediated by distinct regulatory mechanisms.
Zhao Y; Shen X; Zhu Y; Wang A; Xiong Y; Wang L; Fei Y; Wang Y; Wang W; Lin F; Liang Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):333. PubMed ID: 31370861
[TBL] [Abstract][Full Text] [Related]
12. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer.
Zhang W; Wang S; Wang Q; Yang Z; Pan Z; Li L
Oncol Rep; 2014 Mar; 31(3):1334-42. PubMed ID: 24402045
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin L is involved in proliferation and invasion of ovarian cancer cells.
Zhang L; Wei L; Shen G; He B; Gong W; Min N; Zhang L; Duan Y; Xie J; Luo H; Gao X
Mol Med Rep; 2015 Jan; 11(1):468-74. PubMed ID: 25333746
[TBL] [Abstract][Full Text] [Related]
16. Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
Zhang J; Zhao J; Zhang W; Liu G; Yin D; Li J; Zhang S; Li H
Int J Gynecol Cancer; 2012 Nov; 22(9):1450-6. PubMed ID: 23051955
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer.
Fu Z; Wang C; Chen Y; Zhang X; Wang X; Xie X
Pathol Res Pract; 2019 Nov; 215(11):152625. PubMed ID: 31540773
[TBL] [Abstract][Full Text] [Related]
19. Biological characteristics of Taxol‑resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53.
Liu Q; Sui R; Li R; Miao J; Liu J
Mol Med Rep; 2015 Feb; 11(2):1292-7. PubMed ID: 25351378
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
